Cargando…

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS

Detalles Bibliográficos
Autores principales:	Bruchertseifer, Frank, Morgenstern, Alfred, Martinez, Yisel, Cocolios, Thomas, Stora, Thierry
Publicado:	2015
Materias:	Detectors and Experimental Techniques
Acceso en línea:	http://cds.cern.ch/record/2059859

Ejemplares similares

Towards reliable production of 225Ac for medical applications: Systematic analysis of the production of Fr, Ra and Ac beams.
por: Dockx, Kristof, et al.
Publicado: (2017)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Spectroscopic studies of francium 225
por: García-Borge, M J, et al.
Publicado: (1987)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Mass separation of 225Ac for medical applications: first proof of principle at CERN-MEDICIS
por: Heines, Michael
Publicado: (2021)

The CERN-MEDICIS Isotope Separator Beamline
por: Martinez Palenzuela, Yisel, et al.
Publicado: (2021)

The CERN-MEDICIS Isotope Separator Beamline
por: Martinez Palenzuela, Yisel, et al.
Publicado: (2021)

Search for nuclear octupole deformation effects in francium-225
por: García-Borge, M J, et al.
Publicado: (1987)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

Competition between pairing correlations and deformation from the odd-even mass staggering of francium and radium isotopes
por: Kreim, S, et al.
Publicado: (2014)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

Collinear resonance ionization spectroscopy of exotic francium and radium isotopes
por: Wilkins, Shane
Publicado: (2018)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Editorial: MEDICIS-promed: Advances in radioactive ion beams for nuclear medicine
por: Stora, Thierry, et al.
Publicado: (2022)

Editorial: MEDICIS-promed: Advances in radioactive ion beams for nuclear medicine
por: Stora, Thierry, et al.
Publicado: (2022)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Mass determination of francium and radium isotopes by a Penning trap mass spectrometer
por: Bollen, G, et al.
Publicado: (1991)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier
por: Kruijff, R. M. de, et al.
Publicado: (2019)

MEDICIS high level control application
por: Charrondiere, Cedric, et al.
Publicado: (2018)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Beta-decay energies and masses of short-lived isotopes of rubidium, cesium, francium and radium
por: Westgaard, L, et al.
Publicado: (1975)

Beta-decay energies and masses of short-lived isotopes of rubidium, caesium, francium, and radium
por: Westgaard, L, et al.
Publicado: (1975)

Gamma counting protocols for the accurate quantification of (225)Ac and (213)Bi without the need for a secular equilibrium between parent and gamma-emitting daughter
por: Castillo Seoane, Dayana, et al.
Publicado: (2022)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Nuclear ground state spins of the francium isotopes $^{208-213,220-222}$Fr
por: Ekström, C, et al.
Publicado: (1978)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Characterization and optimization of a versatile laser and electron-impact ion source for radioactive ion beam production at ISOLDE and MEDICIS
por: Martinez Palenzuela, Yisel
Publicado: (2019)

Assessment of (213)Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-(13)C]pyruvate and [(18)F]FDG
por: Feuerecker, Benedikt, et al.
Publicado: (2019)

Laser resonance ionization spectroscopy on lutetium for the MEDICIS project
por: Gadelshin, V, et al.
Publicado: (2017)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_musmqubsu6kh8tcfuu1gt2rc1a